How do I write a prescription for tiotropium bromide (Spiriva) for a patient with chronic obstructive pulmonary disease, specifying the appropriate formulation, dosage, administration instructions, quantity, refills, contraindications, and alternative therapy if needed?

How to Write a Prescription for Spiriva (Tiotropium Bromide)

Prescribe Spiriva (tiotropium bromide) 18 mcg inhalation powder capsule, one capsule inhaled once daily via HandiHaler device, for maintenance treatment of COPD. 1

Prescription Components

Drug Name and Formulation

• Generic name: Tiotropium bromide
• Brand name: Spiriva
• Formulation: 18 mcg inhalation powder capsule (delivers 18 mcg tiotropium cation from 22.5 mcg tiotropium bromide)
• Device: HandiHaler dry powder inhaler (DPI)

Dosing Instructions

Write the prescription as follows:

Tiotropium bromide 18 mcg inhalation powder

• Sig: Inhale contents of ONE capsule once daily via HandiHaler device
• Route: Oral inhalation only
• Critical instruction: DO NOT SWALLOW CAPSULES 1
• Timing: Once daily at the same time each day (timing does not affect efficacy) 2

Quantity and Refills

• Quantity: 30 capsules (30-day supply) or 90 capsules (90-day supply)
• Refills: 11 refills for chronic maintenance therapy
• Include HandiHaler device if patient is new to tiotropium

Clinical Indications

Tiotropium is indicated for long-term, once-daily maintenance treatment of bronchospasm associated with COPD 1, 3. This includes:

• Moderate to severe COPD (FEV₁ <60% predicted) as first-line maintenance therapy 4, 5
• Mild COPD (FEV₁ ≥50-70% predicted) where it shows most pronounced improvements 6
• Prevention of COPD exacerbations - reduces exacerbation rate by 20-28% 3, 7

The 2015 ACCP/CTS guideline provides Grade 1A recommendation for long-acting muscarinic antagonists in moderate to severe COPD to prevent acute exacerbations 4.

Contraindications and Precautions

Absolute Contraindications

• Hypersensitivity to tiotropium, ipratropium, or atropine derivatives
• NOT indicated for asthma (different dose and device required - Respimat 2.5 mcg for asthma) 8

Use with Caution

• Moderate to severe renal impairment (CrCl <50 mL/min) - altered pharmacokinetics but dose adjustment not typically required; monitor closely 7
• Narrow-angle glaucoma - avoid powder contact with eyes
• Prostatic hyperplasia or bladder neck obstruction
• Severe hepatic impairment (not studied)

Important Warnings

• Not for acute bronchospasm or rescue therapy - patients need separate short-acting bronchodilator
• Paradoxical bronchospasm possible (discontinue if occurs)
• Anticholinergic effects: dry mouth (6-16% of patients), constipation, urinary retention 3, 7

Patient Education Points

Administration Technique

1. Capsules are for inhalation only via HandiHaler device - never swallow
2. Pierce capsule in device immediately before use
3. Inhale deeply and slowly (DPI requires adequate inspiratory flow)
4. Hold breath for 5-10 seconds after inhalation
5. Exhale away from device
6. Check capsule chamber to ensure powder is gone (may require second inhalation)

Expected Benefits

• Lung function improvement: Trough FEV₁ increases by approximately 120 mL, peak increases by 250 mL 3
• Symptom relief: Reduced dyspnea within first week, maximal benefit by 2-3 weeks 2
• Exacerbation prevention: 20-28% reduction in exacerbations per year 3
• Sustained effect: No tachyphylaxis over 1-year treatment 7

Monitoring

• Assess symptom improvement and dyspnea at 2-4 weeks
• Spirometry at 3-6 months to document objective improvement
• Monitor for anticholinergic side effects (dry mouth most common)

Alternative or Adjunctive Therapy

If Inadequate Response to Tiotropium Alone

Based on BTS and CTS guidelines 9, 5:

For moderate disease:

• Add short-acting β₂-agonist as needed
• Consider corticosteroid trial (prednisolone 30 mg daily × 2 weeks with spirometry) 9

For severe disease:

• Combination therapy: Add long-acting β₂-agonist (LABA)
  • Tiotropium superior to LABA monotherapy for exacerbation prevention 4
  • Combination improves lung function more than either alone 7, 10
• Consider LABA/ICS combination if frequent exacerbations
• Assess for home nebulizer if inadequate response to standard inhalers 9

Comparison with Other Bronchodilators

• Tiotropium vs ipratropium: Tiotropium superior - once-daily dosing, greater bronchodilation, fewer exacerbations 3, 7
• Tiotropium vs salmeterol: Tiotropium at least as effective, possibly superior for exacerbation prevention 4, 7
• Tiotropium vs indacaterol: Non-inferior lung function outcomes 11

Common Pitfalls to Avoid

1. Prescribing for acute exacerbations - tiotropium is maintenance therapy only; use short-acting bronchodilators for acute symptoms 12

2. Wrong device or formulation - HandiHaler uses 18 mcg capsules; Respimat SMI uses different cartridge and dosing (5 mcg for COPD, 2.5 mcg for asthma) 8

3. Inadequate patient education - patients must understand capsules are for inhalation only, not oral ingestion 1

4. Not providing rescue inhaler - all patients need short-acting bronchodilator for breakthrough symptoms 9

5. Ignoring smoking cessation - smoking cessation is essential at all COPD stages and prevents accelerated FEV₁ decline 9

6. Monotherapy in severe COPD - severe disease typically requires combination bronchodilator therapy (LAMA + LABA) 9, 5